These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 34804034)

  • 1. Profiling Tumor Immune Microenvironment of Non-Small Cell Lung Cancer Using Multiplex Immunofluorescence.
    Peng H; Wu X; Zhong R; Yu T; Cai X; Liu J; Wen Y; Ao Y; Chen J; Li Y; He M; Li C; Zheng H; Chen Y; Pan Z; He J; Liang W
    Front Immunol; 2021; 12():750046. PubMed ID: 34804034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiplex immunofluorescence and single-cell transcriptomic profiling reveal the spatial cell interaction networks in the non-small cell lung cancer microenvironment.
    Peng H; Wu X; Liu S; He M; Xie C; Zhong R; Liu J; Tang C; Li C; Xiong S; Zheng H; He J; Lu X; Liang W
    Clin Transl Med; 2023 Jan; 13(1):e1155. PubMed ID: 36588094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophages-based immune-related risk score model for relapse prediction in stage I-III non-small cell lung cancer assessed by multiplex immunofluorescence.
    Wu XR; Peng HX; He M; Zhong R; Liu J; Wen YK; Li CC; Li JF; Xiong S; Yu T; Zheng HB; Chen YH; He JX; Liang WH; Cai XY
    Transl Lung Cancer Res; 2022 Apr; 11(4):523-542. PubMed ID: 35529784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
    Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
    Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
    Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spatial interaction and functional status of CD68
    Liu X; Zhang Z; Yuan J; Yu J; Chen D
    Front Immunol; 2024; 15():1396719. PubMed ID: 38799432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ITGAL expression in non-small-cell lung cancer tissue and its association with immune infiltrates.
    Zhang R; Zhu G; Li Z; Meng Z; Huang H; Ding C; Wang Y; Chen C; Li Y; Liu H; Chen J
    Front Immunol; 2024; 15():1382231. PubMed ID: 38646528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
    Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
    Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
    BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatial cell interplay networks of regulatory T cells predict recurrence in patients with operable non-small cell lung cancer.
    Cai S; Yang G; Hu M; Li C; Yang L; Zhang W; Sun J; Sun F; Xing L; Sun X
    Cancer Immunol Immunother; 2024 Aug; 73(10):189. PubMed ID: 39093404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.
    Parra ER; Villalobos P; Behrens C; Jiang M; Pataer A; Swisher SG; William WN; Zhang J; Lee J; Cascone T; Heymach JV; Forget MA; Haymaker C; Bernatchez C; Kalhor N; Weissferdt A; Moran C; Zhang J; Vaporciyan A; Gibbons DL; Sepesi B; Wistuba II
    J Immunother Cancer; 2018 Jun; 6(1):48. PubMed ID: 29871672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer.
    Li Z; Maeda D; Yoshida M; Umakoshi M; Nanjo H; Shiraishi K; Saito M; Kohno T; Konno H; Saito H; Minamiya Y; Goto A
    Lung Cancer; 2018 Sep; 123():127-135. PubMed ID: 30089583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spatial immunophenotyping of the tumour microenvironment in non-small cell lung cancer.
    Backman M; Strell C; Lindberg A; Mattsson JSM; Elfving H; Brunnström H; O'Reilly A; Bosic M; Gulyas M; Isaksson J; Botling J; Kärre K; Jirström K; Lamberg K; Pontén F; Leandersson K; Mezheyeuski A; Micke P
    Eur J Cancer; 2023 May; 185():40-52. PubMed ID: 36963351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Macrophage Phenotypes in Resectable Non-Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry.
    Rakaee M; Busund LR; Jamaly S; Paulsen EE; Richardsen E; Andersen S; Al-Saad S; Bremnes RM; Donnem T; Kilvaer TK
    Neoplasia; 2019 Mar; 21(3):282-293. PubMed ID: 30743162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.
    Usó M; Jantus-Lewintre E; Bremnes RM; Calabuig S; Blasco A; Pastor E; Borreda I; Molina-Pinelo S; Paz-Ares L; Guijarro R; Martorell M; Forteza J; Camps C; Sirera R
    Oncotarget; 2016 Aug; 7(33):52849-52861. PubMed ID: 27463005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue.
    Parra ER; Ferrufino-Schmidt MC; Tamegnon A; Zhang J; Solis L; Jiang M; Ibarguen H; Haymaker C; Lee JJ; Bernatchez C; Wistuba II
    Sci Rep; 2021 Apr; 11(1):8511. PubMed ID: 33875760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
    Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variants in Epithelial-Mesenchymal Transition and Immune Checkpoint Genes Are Associated With Immune Cell Profiles and Predict Survival in Non-Small Cell Lung Cancer.
    Parra ER; Jiang M; Machado-Rugolo J; Yaegashi LB; Prieto T; Farhat C; de Sá VK; Nagai MA; de Lima VCC; Takagaki T; Terra R; Fabro AT; Capelozzi VL
    Arch Pathol Lab Med; 2020 Oct; 144(10):1234-1244. PubMed ID: 32150457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.